The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2019 | ARROW: carfilzomib dosing in frail R/R multiple myeloma patients
Maria Victoria-Mateos
• 3 Jun 2019
The ARROW study (NCT02412878) investigated the safety and efficacy of once-weekly carfilzomib dosing in frail relapsed/refractory multiple myeloma patients. Maria-Victoria Mateos, MD, PhD, of the Institute of Biomedical Research of Salamanca, Salamanca, Spain, discuses this study at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
